Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Medication Burden in Medically Controlled Patients With Ocular Hypertension or Primary Open Angle Glaucoma

What this Trial Is About

Researchers are evaluating Direct Selective Laser Trabeculoplasty (DSLT) to see if it can reduce the number of medications needed for patients with medically controlled ocular hypertension or primary open angle glaucoma. This prospective, open-label study will measure how well DSLT lowers medication use and intraocular pressure (IOP), as well as monitor the need for additional medications or surgeries over six months. The study is sponsored by The Eye Institute of West Florida and focuses on maintaining target IOP with fewer medications. Participants will receive DSLT treatment using the Voyager DSLT device, which delivers 120 laser shots at the eye's limbus over 2.4 seconds. The laser settings include a 400 micrometer spot size and fixed energy of 1.8 mJ. The procedure aims to reduce medication burden while monitoring IOP. Follow-up visits are scheduled at 1, 3, and 6 months after treatment to assess outcomes. During the study, participants will have their IOP measured at each follow-up using a calibrated Goldmann tonometer. Researchers will track changes in medication use, IOP levels, and the need for any secondary surgical interventions. The primary outcome is the reduction in glaucoma medications at six months compared to baseline. Secondary measures include IOP changes, success rates without medication increase, and medication use proportions. Total study participation lasts six months post-treatment.

DSLT for Reducing Medication in Glaucoma